deCODE genetics (Nasdaq:DCGN) today announced that
it has named Birgit Stattin Norinder to its Board of Directors, effective
immediately.
Ms Norinder has extensive experience in the Pharmaceutical Industry and
has held senior clinical development and regulatory affairs positions in
Europe and the United States at Pfizer, Astra, Glaxo and Pharmacia & Upjohn.
She was CEO and Chairman of UK-based Prolifix Ltd, from 1998 until the merger
of Prolifix and TopoTarget in 2002. She currently serves on the boards of
several biotechnology companies including Antisoma plc, Artimplant AB, Photocure
ASA, Biolipox AB, and is chairman of the board of Betagenon AB.
“We are very pleased to welcome Birgit to our board. She brings with her
a wealth of experience in drug development, both in the world’s biggest pharmaceutical
companies and in a range of biotechnology firms. She is ideally suited to
contribute to our work as we expand our clinical development pipeline and
bring our lead compounds forward to the market,” said Kari Stefansson, CEO
of deCODE.
About deCODE
deCODE genetics (NASDAQ:DCGN) is a global leader in applying human genetics
to develop drugs for common diseases. Our population approach has enabled
us to discover and target key biological pathways involved in conditions
ranging from heart attack to cancer. We are turning these discoveries into
new medicine to better treat and prevent many of the biggest challenges
to public health. deCODE is delivering on the promise of the new genetics.SM
Visit us on the web at www.decode.com.
Any statements contained in this presentation that relate to future plans,
events or performance are forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to a number of risks and uncertainties that could
cause actual results to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, among others, those
relating to technology and product development, integration of acquired
businesses, market acceptance, government regulation and regulatory approval
processes, intellectual property rights and litigation, dependence on collaborative
relationships, ability to obtain financing, competitive products, industry
trends and other risks identified in deCODE’s filings with the Securities
and Exchange Commission. deCODE undertakes no obligation to update or alter
these forward-looking statements as a result of new information, future
events or otherwise.
